INVA News and Press, Innoviva Inc. From 05/24/23

2023-05-24 06:03:52 ET Innoviva ( NASDAQ: INVA ) said the the U.S. Food and Drug Administration (FDA) approved bacterial pneumonia therapy Xacduro. The new drug application (NDA) for Xacduro (sulbactam for injection; durlobactam for injection) was filed by Entasis Th...

Indicated for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia caused by susceptible strains of Acinetobacter First pathogen-targeted therapy addressing Acinetobacter, including resistant strains, an emerging global health threat and gro...

2023-05-22 05:00:00 ET Summary Pharmaceuticals/biotechnology and healthcare providers still have good value scores. Healthcare equipment is the less attractive subsector. Fast facts on IHF, a healthcare providers ETF. 10 stocks cheaper than their peers in May. ...

Sulbactam-durlobactam is the first pathogen-targeted therapy under investigation for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia caused by susceptible strains of Acinetobacter baumannii-calcoaceticus complex (Acinetobacter) . ...

2023-05-09 17:45:34 ET Innoviva press release ( NASDAQ: INVA ): Q1 GAAP EPS of $0.51. Revenue of $76.37M (-15.2% Y/Y). Cash and cash equivalents totaled $144.0 million. Royalty, product sales and milestone receivables totaled $75.8 million as of March 31, 2023. Fir...

Received GSK royalties of $60.3 million, net product revenues of $11.5 million and license revenue of $8.0 million in the first quarter of 2023 Repurchased $40.3 million of common stock and paid off $96.2 million of 2023 convertible notes Innoviva, Inc. (NASDAQ: INVA) (“I...

2023-04-29 16:00:00 ET With the first trading day in May coming on Monday, many pharmaceutical companies will be hoping their returns fare better than they did in April. The iShares U.S. Pharmaceuticals ETF ( IHE ) returned a paltry 1.6% in April. The ETF's top two holdings are ...

2023-04-28 17:45:51 ET Innoviva ( NASDAQ: INVA ) announced on Friday that chairman George Bickerstaff, III, would not stand for reelection at the company’s 2023 Annual Meeting. After the meeting, assuming that all other members are reelected, the board will c...

Innoviva, Inc. (NASDAQ: INVA) (“Innoviva” and “the Company”) and George Bickerstaff, III, Chairman of the Board of Directors of the Company (the “Board”) today announced that Mr. Bickerstaff would not stand for reelection at the Company’s 2023 Annu...

2023-04-17 17:27:00 ET Innoviva ( NASDAQ: INVA ) said the U.S. Food and Drug Administration's advisory committee unanimously voted in support of approval of sulbactam-durlobactam to treat hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia...